| Literature DB >> 31620020 |
Yu-Tang Tung1,2,3, Yi-Ju Hsu4, Chen-Chung Liao5, Shang-Tse Ho6, Chi-Chang Huang1,4, Wen-Ching Huang7.
Abstract
Regular exercise prevents lipid abnormalities and conditions such as diabetes mellitus, hypertension, and obesity; it considerably benefits sedentary individuals. However, individuals exhibit highly variable responses to exercise, probably due to genetic variations. Animal models are typically used to investigate the relationship of intrinsic exercise capacity with physiological, pathological, psychological, behavioral, and metabolic disorders. In the present study, we investigated differential physiological adaptations caused by intrinsic exercise capacity and explored the regulatory molecules or mechanisms through multiomics approaches. Outbred ICR mice (n = 100) performed an exhaustive swimming test and were ranked based on the exhaustive swimming time to distinguish intrinsically high- and low-capacity groups. Exercise performance, exercise fatigue indexes, glucose tolerance, and body compositions were assessed during the experimental processes. Furthermore, the gut microbiota, transcriptome, and proteome of soleus muscle with intrinsically high exercise capacity (HEC) and low exercise capacity (LEC) were further analyzed to reveal the most influential factors associated with differential exercise capacities. HEC mice outperformed LEC mice in physical activities (exhaustive swimming and forelimb grip strength tests) and exhibited higher glucose tolerance than LEC mice. Exercise-induced peripheral fatigue and the level of injury biomarkers (lactate, ammonia, creatine kinase, and aspartate aminotransferase) were also significantly lower in HEC mice than in LEC mice. Furthermore, the gut of the HEC mice contained significantly more Butyricicoccus than that of the LEC mice. In addition, transcriptome data of the soleus muscle revealed that the expression of microRNAs that are strongly associated with exercise performance-related physiological and metabolic functions (i.e., miR-383, miR-107, miR-30b, miR-669m, miR-191, miR-218, and miR-224) was higher in HEC mice than in LEC mice. The functional proteome data of soleus muscle indicated that the levels of key proteins related to muscle function and carbohydrate metabolism were also significantly higher in HEC mice than in LEC mice. Our study demonstrated that the mice with various intrinsic exercise capacities have different gut microbiome as well as transcriptome and proteome of soleus muscle by using multiomics approaches. The specific bacteria and regulatory factors, including miRNA and functional proteins, may be highly correlated with the adaptation of physiological functions and exercise capacity.Entities:
Keywords: gut microbiota; intrinsic exercise capacity; physical activities; proteome; transcriptome
Year: 2019 PMID: 31620020 PMCID: PMC6759823 DOI: 10.3389/fphys.2019.01201
Source DB: PubMed Journal: Front Physiol ISSN: 1664-042X Impact factor: 4.566
FIGURE 1Capacity ranking from low to high for male mice (n = 100). The 15 lowest ranked, 15 medium ranked, and 15 highest ranked mice were categorized as low exercise capacity (LEC), medium exercise capacity (MEC), and high exercise capacity (HEC) mice for study experiments.
FIGURE 2Effect of exercise capacity on (A) exhaustive swimming time and (B) forelimb grip strength. Data are presented as mean ± standard deviation for 15 mice per group. Different letters (a,b,c) indicate a significant difference at p < 0.05 using one-way ANOVA.
Effect of different exercise capacities on general characteristics.
| Initial BW (g) | 35.3 ± 0.7 | 34.8 ± 0.7 | 34.4 ± 0.6 | 0.9655 |
| Final BW (g) | 39.5 ± 0.7 | 40.1 ± 0.9 | 39.6 ± 0.5 | 0.2490 |
| Food intake (g/day) | 7.9 ± 0.4 | 7.5 ± 0.3 | 7.8 ± 0.3 | 0.9344 |
| Water intake (mL/day) | 11.8 ± 0.4 | 10.9 ± 0.4 | 10.9 ± 0.2 | 0.2374 |
| Liver (g) | 2.27 ± 0.07 | 2.22 ± 0.05 | 2.25 ± 0.07 | 0.8609 |
| Muscle (g) | 0.39 ± 0.02a | 0.40 ± 0.01ab | 0.42 ± 0.01b | 0.0504 |
| Kidney (g) | 0.71 ± 0.02 | 0.70 ± 0.01 | 0.70 ± 0.02 | 0.8611 |
| Heart (g) | 0.26 ± 0.01 | 0.25 ± 0.01 | 0.25 ± 0.01 | 0.9842 |
| Lung (g) | 0.21 ± 0.01 | 0.21 ± 0.01 | 0.22 ± 0.01 | 0.9729 |
| EFP (g) | 0.29 ± 0.03 | 0.26 ± 0.02 | 0.27 ± 0.01 | 0.9388 |
| BAT (g) | 0.09 ± 0.001a | 0.11 ± 0.006b | 0.09 ± 0.002a | 0.3432 |
FIGURE 3Effect of exercise capacity on fatigue-related biomarkers, namely serum (A) lactate, (B) ammonia, (C) blood urea nitrogen (BUN), and (D) glucose level, after the acute exercise challenge. Data are presented as mean ± standard deviation for 15 mice in each group. Different letters (a,b,c) indicate a significant difference at p < 0.05 using one-way ANOVA.
FIGURE 4Effect of exercise capacity on injury-related markers, namely serum (A) lactic dehydrogenase (LDH), (B) creatinine kinase (CK), (C) aspartate aminotransferase (AST), and (D) alanine transaminase (ALT) levels, after the acute exercise challenge. Data are presented as mean ± standard deviation for 15 mice in each group. Different letters (a,b,c) indicate a significant difference at p < 0.05 using one-way ANOVA.
Effect of different exercise capacity on biochemical analysis at the end of treatment.
| AST (U/L) | 70 ± 4 | 81 ± 4 | 73 ± 3 | 0.545 |
| ALT (U/L) | 44 ± 3a | 61 ± 4b | 54 ± 2ab | 0.022 |
| LDH (U/L) | 246 ± 12a | 387 ± 27b | 333 ± 24ab | 0.034 |
| Albumin (g/dL) | 3.2 ± 0.03a | 3.3 ± 0.04b | 3.4 ± 0.06b | 0.046 |
| TP (g/dL) | 4.6 ± 0.1 | 4.6 ± 0.1 | 4.6 ± 0.1 | 0.757 |
| BUN (mg/dL) | 23.5 ± 0.7b | 20.4 ± 0.7a | 21.1 ± 0.4a | 0.003 |
| Alk-P (U/L) | 38.4 ± 1.8a | 47.9 ± 3.3b | 45.6 ± 2.6ab | 0.017 |
| Creatinine (mg/dL) | 0.13 ± 0.01 | 0.13 ± 0.01 | 0.12 ± 0.01 | 0.590 |
| CK (U/L) | 286 ± 41 | 307 ± 37 | 285 ± 46 | 0.911 |
| UA (mg/dL) | 1.5 ± 0.1 | 1.7 ± 0.1 | 1.6 ± 0.1 | 0.646 |
| TC (mg/dL) | 126 ± 6 | 137 ± 5 | 136 ± 4 | 0.301 |
| TG (mg/dL) | 141 ± 9 | 151 ± 9 | 139 ± 9 | 1.000 |
| Glu (mg/dL) | 157 ± 6 | 152 ± 7 | 159 ± 5 | 0.870 |
FIGURE 5The oral glucose tolerance test was performed in mice with various exercise capacities at the same glucose dosage (2 g/kg) after 14 h of fasting. The indicated sampling times (0, 15, 30, 60, and 120 min) were plotted as the tolerance curve. Data are presented as mean ± standard deviation for 15 mice in each group. Different letters (a,b,c) indicate a significant difference at p < 0.05 using one-way ANOVA.
FIGURE 6Effect of exercise capacity on (A) partial least squares discriminant analysis (PLSDA) of genus level, (B) alpha-diversity indexes of the gut microbiota composition, and (C) Butyricicoccus. Different letters (a,b) indicate a significant difference at p < 0.05 using one-way ANOVA.
Effect of different exercise capacities on miRNA expression.
| mmu-miR-878-3p-002541 | 1.77 | 27.13 | 27.13 |
| mmu-miR-383-4381093 | 1.18 | 18.43 | 18.43 |
| mmu-miR-719-001673 | 2.40 | 13.50 | 13.50 |
| mmu-miR-672-4395438 | 2.52 | 12.22 | 12.22 |
| mmu-miR-423-5p-4395451 | 2.54 | 12.11 | 12.11 |
| hsa-miR-183#-002270 | 2.76 | 10.80 | 10.80 |
| mmu-miR-183-4395380 | 1.51 | 10.19 | 10.19 |
| mmu-miR-466b-3-3p-002500 | 6.42 | 10.12 | 10.12 |
| mmu-miR-543-4395487 | 1.69 | 9.77 | 9.77 |
| hsa-miR-338-000548 | 2.92 | 9.36 | 9.36 |
| mmu-miR-137-4373301 | 7.21 | 9.22 | 9.22 |
| mmu-miR-298-4395728 | 3.61 | 8.67 | 8.67 |
| mmu-miR-34c-4373036 | 1.16 | 7.23 | 7.23 |
| mmu-miR-466h-4395646 | 6.52 | 7.00 | 7.00 |
| mmu-miR-465b-5p-4395615 | 3.16 | 6.73 | 6.73 |
| rno-miR-347-4381114 | 2.75 | 6.49 | 6.49 |
| mmu-miR-743a-4395599 | 2.54 | 6.39 | 6.39 |
| mmu-miR-330-4395341 | 1.77 | 6.00 | 6.00 |
| mmu-miR-181A-2#-002687 | 1.19 | 5.58 | 5.58 |
| mmu-miR-182-4395729 | 1.99 | 5.52 | 5.52 |
| mmu-miR-1962-121173_mat | 9.72 | 5.47 | 5.47 |
| mmu-miR-362-5p-002614 | 5.55 | 5.25 | 5.25 |
| mmu-miR-1193-002794 | 3.78 | 4.83 | 4.83 |
| mmu-miR-455-4395585 | 3.82 | 4.74 | 4.74 |
| mmu-miR-107-4373154 | 3.68 | 4.55 | 4.55 |
| mmu-miR-450a-5p-4395414 | 1.88 | 4.20 | 4.20 |
| hsa-miR-9#-002231 | 7.62 | 4.00 | 4.00 |
| mmu-miR-30b#-002498 | 2.54 | 3.98 | 3.98 |
| rno-miR-207-4381096 | 1.30 | 3.92 | 3.92 |
| mmu-miR-669m-121190_mat | 4.72 | 3.92 | 3.92 |
| mmu-miR-294-4373326 | 2.61 | 3.84 | 3.84 |
| mmu-miR-138#-002554 | 2.14 | 3.78 | 3.78 |
| mmu-miR-191#-002576 | 3.08 | 3.68 | 3.68 |
| rno-miR-20b-001326 | 7.61 | 3.60 | 3.60 |
| mmu-miR-20b-4373263 | 1.26 | 3.54 | 3.54 |
| mmu-miR-10a-4373153 | 1.97 | 3.53 | 3.53 |
| mmu-miR-433-4373205 | 1.89 | 3.47 | 3.47 |
| mmu-miR-1896-121128_mat | 7.14 | 3.41 | 3.41 |
| mmu-miR-218-1#-002552 | 2.00 | 3.31 | 3.31 |
| mmu-miR-202-3p-4373311 | 1.86 | 3.21 | 3.21 |
| mmu-miR-501-3p-4381069 | 7.69 | 3.10 | 3.10 |
| mmu-miR-470-4395718 | 2.66 | 3.10 | 3.10 |
| mmu-miR-434-5p-4395711 | 4.27 | 3.09 | 3.09 |
| mmu-miR-211-4373315 | 3.44 | 3.08 | 3.08 |
| rno-miR-224-4373187 | 8.47 | 3.04 | 3.04 |
| rno-miR-1-4395765 | 2.90E−01 | 0.22 | −4.65 |
| mmu-miR-1188-002866 | 2.50E−01 | 0.03 | −39.44 |
Soleus miRNA molecules with significant difference related to intrinsic exercise capacity.
| miR-383 | (1) Testosterone and progesterone regulation, (2) spermatogenesis, and (3) steroidogenesis | 18.43 | 1.18 |
| miR-107 | Insulin sensitivity | 4.55 | 3.68 |
| miR-30b | Role of regeneration | 3.98 | 2.54 |
| miR-669m | Adaptation during toxic metabolites accumulation | 3.92 | 4.72 |
| miR-191 | Adipogenesis inhibition | 3.68 | 3.08 |
| miR-218 | Vascular organization | 3.31 | 2.00 |
| miR-224 | Adipogenesis regulation (fatty acid metabolism) | 3.04 | 8.47 |
Differential expression for protein molecules in soleus between low exercise capacity (LEC) and high exercise capacity (HEC) groups.
| Myosin, heavy polypeptide 6, cardiac muscle, alpha | Q2TAW4 | Q2TAW4 | 107.87 ± 26.34 | 10.53 ± 8.55 | 0.01259 |
| Calsequestrin | Q6P3C3 | Q6P3C3 | 28.3 ± 3.34 | 16.57 ± 2.29 | 0.02739 |
| Calsequestrin-1 | O09165 | CASQ1 | 28.3 ± 3.34 | 16.57 ± 2.29 | 0.02739 |
| Beta-enolase | P21550 | ENOB | 12.88 ± 1.82 | 5.19 ± 0.97 | 0.00971 |
| Cytochrome b–c1 complex subunit 1, mitochondrial | Q9CZ13 | QCR1 | 3.84 ± 0.56 | 1.62 ± 0.71 | 0.04955 |
| Putative uncharacterized protein | Q3THM1 | Q3THM1 | 3.84 ± 0.56 | 1.62 ± 0.71 | 0.04955 |
| Putative uncharacterized protein | Q3TIC8 | Q3TIC8 | 3.84 ± 0.56 | 1.62 ± 0.71 | 0.04955 |
| Putative uncharacterized protein | Q3UIQ2 | Q3UIQ2 | 9.02 ± 1.44 | 1.77 ± 1.77 | 0.01918 |
| Putative uncharacterized protein | Q3TX47 | Q3TX47 | 2.18 ± 0.79 | 0 ± 0 | 0.03254 |
| Adenylosuccinate synthetase isozyme 1 | P28650 | PURA1 | 2.37 ± 0.46 | 0 ± 0 | 0.00222 |
| Adenylosuccinate synthetase isozyme 1 | J3QN31 | J3QN31 | 2.37 ± 0.46 | 0 ± 0 | 0.00222 |
| Glucose-6-phosphate isomerase | P06745 | G6PI | 10.88 ± 2.67 | 3.96 ± 0.42 | 0.04274 |
| Putative uncharacterized protein | Q3U6X6 | Q3U6X6 | 5.1 ± 1.95 | 0 ± 0 | 0.03993 |
| Phosphoglucomutase-1 | A2CEK3 | A2CEK3 | 5.1 ± 1.95 | 0 ± 0 | 0.03993 |
| Myosin light chain 3 | P09542 | MYL3 | 1.98 ± 0.75 | 5.83 ± 1.35 | 0.04648 |
| Synaptopodin 2 | B2RY03 | B2RY03 | 6.48 ± 0.7 | 5.07 ± 0.92 | 0.26857 |
| Synaptopodin-2 | E9Q1U2 | E9Q1U2 | 6.48 ± 0.7 | 5.07 ± 0.92 | 0.26857 |
| Serum deprivation-response protein | Q63918 | SDPR | 1.19 ± 0.41 | 0 ± 0 | 0.02615 |
| 2-Oxoglutarate dehydrogenase, mitochondrial | Q60597 | ODO1 | 10.05 ± 1.85 | 14.69 ± 1.04 | 0.07145 |
| Moesin | P26041 | MOES | 0 ± 0 | 0.37 ± 0.37 | 0.35592 |
| Nucleoside diphosphate kinase A | P15532 | NDKA | 0 ± 0 | 0.37 ± 0.37 | 0.35592 |
| Nucleoside diphosphate kinase B | Q01768 | NDKB | 0 ± 0 | 0.37 ± 0.37 | 0.35592 |
| Putative uncharacterized protein | Q3TZQ2 | Q3TZQ2 | 0 ± 0 | 0.37 ± 0.37 | 0.35592 |
| Radixin | P26043 | RADI | 0 ± 0 | 2.23 ± 1.01 | 0.06861 |
| 6-Phosphofructokinase, muscle type | P47857 | K6PF | 2.05 ± 0.75 | 0 ± 0 | 0.03472 |
| Polymerase I and transcript release factor | O54724 | PTRF | 3.28 ± 0.44 | 1.2 ± 0.7 | 0.04571 |
| Triosephosphate isomerase | P17751 | TPIS | 5.18 ± 1.06 | 0.97 ± 0.56 | 0.01249 |
| Synaptopodin 2-like protein | Q8BWB1 | SYP2L | 3.32 ± 0.21 | 1.55 ± 0.58 | 0.02826 |
| Synaptopodin 2-like protein | B2RQK7 | B2RQK7 | 3.32 ± 0.21 | 1.55 ± 0.58 | 0.02826 |
| Synaptopodin 2-like protein | D3YU08 | D3YU08 | 3.32 ± 0.21 | 1.55 ± 0.58 | 0.02826 |
| Putative uncharacterized protein | Q3UDU4 | Q3UDU4 | 8.93 ± 2.6 | 2.12 ± 0.71 | 0.04491 |
| Uncharacterized protein | M0QWZ0 | M0QWZ0 | 17.19 ± 4.16 | 6.94 ± 0.38 | 0.04961 |
| PDZ and LIM domain protein 5 | Q9CRA2 | Q9CRA2 | 1.74 ± 0.59 | 0 ± 0 | 0.02664 |
| Nucleoside diphosphate kinase | E9PZF0 | E9PZF0 | 2.31 ± 0.29 | 0.62 ± 0.62 | 0.04843 |
| Aspartate aminotransferase, mitochondrial | P05202 | AATM | 3.98 ± 1.62 | 0 ± 0 | 0.04945 |
| Collagen alpha-1(XV) chain | O35206 | COFA1 | 1.24 ± 0.43 | 0 ± 0 | 0.02871 |
| Collagen alpha-1(XV) chain | A2AJY2 | A2AJY2 | 1.24 ± 0.43 | 0 ± 0 | 0.02871 |
| Collagen alpha-1(XV) chain | A2AJY7 | A2AJY7 | 1.24 ± 0.43 | 0 ± 0 | 0.02871 |
| Ryanodine receptor 1 | E9PZQ0 | RYR1 | 1.67 ± 0.59 | 0 ± 0 | 0.02968 |
| Ryanodine receptor 1 | K3W4M2 | K3W4M2 | 1.67 ± 0.59 | 0 ± 0 | 0.02968 |
| Glyceraldehyde-3-phosphate dehydrogenase | P16858 | G3P | 22.26 ± 1.68 | 7.88 ± 0.83 | 0.00026 |
| Very long-chain-specific acyl-CoA dehydrogenase, mitochondrial | P50544 | ACADV | 3.18 ± 0.55 | 0 ± 0 | 0.00119 |
| Protein Mybpc1 | D3YU50 | D3YU50 | 23.96 ± 1.47 | 11.29 ± 3.15 | 0.01081 |
| Protein Mybpc1 | Q6P6L5 | Q6P6L5 | 23.96 ± 1.47 | 11.29 ± 3.15 | 0.01081 |
| Troponin T, fast skeletal muscle | A2A6H6 | A2A6H6 | 23.17 ± 1.95 | 12.68 ± 1.01 | 0.00309 |
| Troponin T, fast skeletal muscle | A2A6I8 | A2A6I8 | 23.17 ± 1.95 | 12.68 ± 1.01 | 0.00309 |
| Troponin T, fast skeletal muscle | A2A6J0 | A2A6J0 | 23.17 ± 1.95 | 12.68 ± 1.01 | 0.00309 |
| Troponin T, fast skeletal muscle | A2A6J1 | A2A6J1 | 23.17 ± 1.95 | 12.68 ± 1.01 | 0.00309 |
| Troponin T, fast skeletal muscle | J3QP61 | J3QP61 | 23.17 ± 1.95 | 12.68 ± 1.01 | 0.00309 |
| Phosphoglucomutase-1 | Q9D0F9 | PGM1 | 11.11 ± 1.02 | 6.84 ± 0.89 | 0.01973 |
| Actin, alpha skeletal muscle | P68134 | ACTS | 132.76 ± 8.24 | 96.79 ± 6.47 | 0.0139 |
| Alpha-actinin-3 | O88990 | ACTN3 | 32.2 ± 3.49 | 21.89 ± 1.75 | 0.03854 |
| Actin, alpha cardiac muscle 1 | P68033 | ACTC | 132.76 ± 8.24 | 96.79 ± 6.47 | 0.0139 |
| Putative uncharacterized protein | Q3TG92 | Q3TG92 | 132.76 ± 8.24 | 96.79 ± 6.47 | 0.0139 |
| Putative uncharacterized protein | Q9CXK3 | Q9CXK3 | 132.76 ± 8.24 | 96.79 ± 6.47 | 0.0139 |
| LIM domain-binding protein 3 | E9PYJ9 | E9PYJ9 | 15.02 ± 1.72 | 9.84 ± 1.22 | 0.0494 |
| G5E8N5 | G5E8N5 | 11.76 ± 0.94 | 2.12 ± 0.71 | 0.00018 | |
| P06151 | LDHA | 11.76 ± 0.94 | 2.12 ± 0.71 | 0.00018 | |
| Putative uncharacterized protein | Q3TI99 | Q3TI99 | 11.76 ± 0.94 | 2.12 ± 0.71 | 0.00018 |
| Collagen alpha-1(XV) chain | A2AJY5 | A2AJY5 | 1.24 ± 0.43 | 0 ± 0 | 0.02871 |
| MCG140784 | Q792Z1 | Q792Z1 | 31.39 ± 1.84 | 25.1 ± 1.58 | 0.04076 |
| Try10-like trypsinogen | Q7M754 | Q7M754 | 31.39 ± 1.84 | 25.1 ± 1.58 | 0.04076 |
| Alpha-enolase | P17182 | ENOA | 2.11 ± 0.72 | 0 ± 0 | 0.02591 |
| Krt6b protein | Q0VDR7 | Q0VDR7 | 25.65 ± 3.96 | 4.94 ± 1.75 | 0.00306 |
| 60S ribosomal protein L7a | P12970 | RL7A | 2.63 ± 0.6 | 0 ± 0 | 0.00448 |
| MCG18601 | D3YVE6 | D3YVE6 | 2.63 ± 0.6 | 0 ± 0 | 0.00448 |
| Ribosomal protein L7A | Q5EBG5 | Q5EBG5 | 2.63 ± 0.6 | 0 ± 0 | 0.00448 |
| Ribosomal protein L7A | Q6P1A9 | Q6P1A9 | 2.63 ± 0.6 | 0 ± 0 | 0.00448 |
| Uncharacterized protein | D3YXT4 | D3YXT4 | 2.63 ± 0.6 | 0 ± 0 | 0.00448 |
| Uncharacterized protein | L7N202 | L7N202 | 2.63 ± 0.6 | 0 ± 0 | 0.00448 |
| Troponin T, fast skeletal muscle | Q9QZ47 | TNNT3 | 15.56 ± 3.67 | 5.59 ± 0.51 | 0.03597 |
| Transitional endoplasmic reticulum ATPase | Q01853 | TERA | 7.78 ± 1.31 | 4.11 ± 0.71 | 0.04918 |
| Uncharacterized protein | D3YU93 | D3YU93 | 1.54 ± 0.54 | 0 ± 0 | 0.02921 |
| Uncharacterized protein | F6U2H0 | F6U2H0 | 1.54 ± 0.54 | 0 ± 0 | 0.02921 |
| Tropomyosin beta chain | P58774 | TPM2 | 76.85 ± 19.02 | 15 ± 7.44 | 0.02316 |
| M-protein | O55124 | O55124 | 13.57 ± 2.5 | 2.39 ± 1.52 | 0.00882 |
| Myomesin 2 | Q14BI5 | Q14BI5 | 13.57 ± 2.5 | 2.39 ± 1.52 | 0.00882 |
| Putative uncharacterized protein | Q3UQS9 | Q3UQS9 | 13.57 ± 2.5 | 2.39 ± 1.52 | 0.00882 |
| Carbonic anhydrase 3 | P16015 | CAH3 | 9.75 ± 1.1 | 2.97 ± 1.45 | 0.00967 |
| Creatine kinase M-type | P07310 | KCRM | 37.66 ± 4.36 | 7.89 ± 2.65 | 0.00112 |
| Putative uncharacterized protein | Q9D6U7 | Q9D6U7 | 37.66 ± 4.36 | 7.89 ± 2.65 | 0.00112 |
| Myosin-binding protein C, fast-type | Q5XKE0 | MYPC2 | 27.79 ± 2.85 | 13.96 ± 3.22 | 0.01815 |
| 6-Phosphofructokinase | Q99K08 | Q99K08 | 2.05 ± 0.75 | 0 ± 0 | 0.03472 |
| Pyruvate carboxylase | E9QPD7 | E9QPD7 | 3.33 ± 1.17 | 0 ± 0 | 0.02909 |
| Pyruvate carboxylase | G5E8R3 | G5E8R3 | 3.33 ± 1.17 | 0 ± 0 | 0.02909 |
| Pyruvate carboxylase | Q3T9S7 | Q3T9S7 | 3.33 ± 1.17 | 0 ± 0 | 0.02909 |
| Pyruvate carboxylase | Q3TCQ3 | Q3TCQ3 | 3.33 ± 1.17 | 0 ± 0 | 0.02909 |
| Pyruvate carboxylase, mitochondrial | Q05920 | PYC | 3.33 ± 1.17 | 0 ± 0 | 0.02909 |
| Synaptopodin-2 | D3YVV9 | D3YVV9 | 1.41 ± 0.49 | 5.07 ± 0.92 | 0.01295 |
| Collagen alpha-2(I) chain | Q01149 | CO1A2 | 3.53 ± 0.49 | 5.77 ± 0.76 | 0.04821 |
| Putative uncharacterized protein | Q3TU64 | Q3TU64 | 3.53 ± 0.49 | 5.77 ± 0.76 | 0.04821 |
| Collagen alpha-1(I) chain | P11087 | CO1A1 | 8.24 ± 0.2 | 13.2 ± 1.33 | 0.01023 |
| Microtubule-associated protein | E9PWC0 | E9PWC0 | 0.38 ± 0.38 | 2.14 ± 0.29 | 0.01021 |
| Microtubule-associated protein | E9PZ43 | E9PZ43 | 0.38 ± 0.38 | 2.14 ± 0.29 | 0.01021 |
| Putative uncharacterized protein | Q8BIZ5 | Q8BIZ5 | 31.15 ± 1.84 | 48.14 ± 5.33 | 0.0235 |
| Terminal uridylyltransferase 4 | B2RX14 | TUT4 | 31.15 ± 1.84 | 48.14 ± 5.33 | 0.0235 |
| Terminal uridylyltransferase 4 | A2A8R7 | A2A8R7 | 31.15 ± 1.84 | 48.14 ± 5.33 | 0.0235 |